# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and lowers the pri...
Preliminary Third Quarter Financial Results (unaudited)Total CHEMOSAT and HEPZATO KIT revenue of approximately $20.5 millionHEP...
Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic live...
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the pri...
Delcath Systems (NASDAQ:DCTH) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.02...